Amino acid change 335 E to K affects the sialic-acid-binding and neuraminidase activities of Urabe AM9 mumps virus hemagglutinin-neuraminidase glycoprotein

Microbes and Infection

Volumn 9, Issue 2, 2007, Pages 234-240

  Reyes Leyva, Julio ^a   Baños, Rocío ^a,b   Borraz Argüello, María ^a,b   Santos López, Gerardo ^a   Rosas, Nora ^a,b   Alvarado, Gabriela ^a,b   Herrera, Irma ^b   Vallejo, Verónica ^a   Tapia Ramírez, José ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Hemagglutinin neuraminidase; Kinetics; Mumps virus; Neurovirulence; Point mutation; Sialic acids; Sialidase; Vaccine

Indexed keywords

AMINO ACID; HN PROTEIN; MEASLES MUMPS VACCINE; SIALIC ACID; SIALIDASE; SIALYL ALPHA 2,3 LACTOSE; SIALYL ALPHA 2,6 LACTOSE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DIVISION; CONTROLLED STUDY; CYTOCHEMISTRY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROLYSIS; MUMPS VIRUS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SAMBUCUS NIGRA; VERO CELL; VIRUS ISOLATION;

AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; HN PROTEIN; HUMANS; MUMPS VIRUS; MUTATION, MISSENSE; N-ACETYLNEURAMINIC ACID; RECEPTORS, VIRUS; VIRUS ATTACHMENT;

MUMPS VIRUS; SAMBUCUS NIGRA;

EID: 33846999900     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2006.11.011     Document Type: Article

References (30)

1. Carbone K.M., and Wolinsky J.S. Mumps virus. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 4th edtion (2001), Lippincott, Williams & Wilkins, Philadelphia 1381-1400
2. Galazka A.M., Robertson S.E., and Kraigher A. Mumps and mumps vaccine: a global review. Bull. WHO 77 (1999) 3-14
3. Centers for Disease Control and Prevention (CDC). Mumps epidemic-Iowa, 2006. Morb. Mortal. Wkly. Rep. 55 (2006) 366-368
4. Nascimento-Carvalho C.M., and Moreno-Carvalho O.A. Frequency of lymphocytic meningitis associated with mumps before and after a mass campaign for mumps vaccination in children from Salvador, Northeast Brazil. Arq. Neuropsiquiatr. 61 (2003) 728-730
5. Dourado I., Cunha S., Teixeira M.G., Farrington C.P., Melo A., Lucena R., and Barreto M.L. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: Implications for immunization programs. Am. J. Epidemiol. 151 (2000) 524-530
6. Brown E.G., Dimock K., and Wright K.E. The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease. J. Infect. Dis. 174 (1996) 619-622
7. Cusi M.G., Santini L., Bianchi S., Valassina M., and Valensin P.E. Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in wild-type strains of mumps virus is the most relevant marker of virulence. J. Clin. Microbiol. 36 (1998) 3743-3744
8. Wright K.E., Dimock K., and Brown E.G. Biological characteristics of genetic variants of Urabe AM9 mumps vaccine virus. Virus Res. 67 (2000) 49-57
9. Afzal M.A., Yates P.J., and Minor P.D. Nucleotide sequence at position 1081 of the Hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain. J. Infect. Dis. 177 (1998) 265-266
10. Cusi M.G., Fisher S., Sedlmeier R., Valassina M., Valensin P.E., Donati M., and Neubert W.J. Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein. Virus Res. 74 (2001) 133-137
11. Amexis G., Fineschi N., and Chumakov K. Correlation of genetic variability with safety of mumps vaccine Urabe AM9 strain. Virology 287 (2001) 234-241
12. Rubin S.A., Amexis G., Pletnikov M., Li Z., Vanderzanden J., Mauldin J., Sauder C., Malik T., Chumakov K., and Carbone K.M. Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype. J. Virol. 77 (2003) 11616-11624
13. Rafiefard F., Johansson B., Tecle T., and Örvell C. Characterization of mumps virus strains with varying neurovirulence. Scand. J. Infect. Dis. 37 (2005) 330-337
14. Sauder C.J., Vanderburgh K.M., Iskow R.C., Malik T., Carbone K.M., and Rubin S.A. Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity. Virology 350 (2006) 48-57
15. Santos-López G., Cruz C., Pazos N., Vallejo V., Reyes-Leyva J., and Tapia-Ramirez J. Two clones obtained from Urabe AM9 mumps virus vaccine differ in their replicative efficiency in neuroblastoma cells. Microbes Infect. 332 (2006) 332-339
16. Reyes-Leyva J., Espinosa B., Hernandez J., Zenteno R., Vallejo V., Hernandez-Jauregui P., and Zenteno E. NeuAcα2, 3Gal-glycoconjugate expression determines cell susceptibility to the Porcine rubulavirus LPMV. Comp. Biochem. Physiol. B. 118B (1997) 327-332
17. Strenge K., Schauer R., Bovin N., Hasegawa A., Ishida H., Kiso M., and Kelm S. Glycan specificity of myelin-associated glycoprotein and sialoadhesin deduced from interactions with synthetic oligosaccharides. Eur. J. Biochem. 258 (1998) 677-685
18. Jensik S.C., and Silver S. Polypeptides of mumps virus. J. Virol. 17 (1976) 363-373
19. Santos-López G., Flores E., Baños R., Herrera-Camacho I., and Reyes-Leyva J. Purification of Porcine rubulavirus attachment protein by isoelectric focusing. Prot. Expr. Purif. 35 (2004) 120-125
20. Segel I.H. Enzyme Kinetics. Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (1975), Wiley, New York pp. 346-464
21. Eash S., Tavares R., Stopa E.G., Robbins S.H., Brossay L., and Atwood W.J. Differential distribution of the JC virus receptor-type sialic acid in normal human tissues. Am. J. Pathol. 164 (2004) 419-424
22. Connaris H., Takimoto T., Russell R., Crennell S., Moustafa I., Portner A., and Taylor G. Probing the sialic binding site of the hemagglutinin-neuraminidase of Newcastle disease virus. Identification of key amino acids involved in cell binding, catalysis and fusion. J. Virol. 76 (2002) 1816-1824
23. Murrell M.T., Porotto M., Greengard O., Poltoratskaia N., and Moscona A. A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity. J. Virol. 75 (2001) 6310-6320
24. Schweighardt B., and Atwood W.J. Virus receptors in the human central nervous system. J. Neurovirol. 7 (2001) 187-195
25. Seidenfaden R., and Hildebrandt H. Retinoic acid-induced changes in polysialyltransferase mRNA expression and NCAM polysialylation in human neuroblastoma cells. J. Neurobiol. 46 (2001) 11-28
26. Suzuki T., Portner A., Scroggs R.A., Uchikawa M., Koyama N., Matsuo K., Suzuki Y., and Takimoto T. Receptor specificities of human respiroviruses. J. Virol. 75 (2001) 4604-4613
27. Ward A.C. Changes in the neuraminidase of neurovirulent influenza virus strains. Virus Genes 10 (1995) 253-260
28. Yamamoto-Goshima F., Maeno K., Morishita T., Ueda M., Fujita Y., Nakajima K., and Yoshii S. Role of neuraminidase in the morphogenesis of influenza B virus. J. Virol. 68 (1994) 1250-1254
29. Porotto M., Murrell M., Greengard O., Doctor L., and Moscona A. Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein. J. Virol. 79 (2005) 2383-2392
30. Solorzano A., Zheng H., Fodor E., Brownlee G.G., Palese P., and Garcia-Sastre A. Reduced levels of neuraminidase of influenza A viruses correlate with attenuated phenotypes in mice. J. Gen. Virol. 81 (2000) 737-742